Peter Lakatos

Academic title(s): 

Professor, Department of Medicine, McGill University

Peter Lakatos
Contact Information

McGill University Health Centre, Montreal General Hospital site 
1650 Ave. Cedar, D16.173.1,Montreal, QC, H3G 1A4
Tel: 514-934-1934, Fax: 514-934-4452

Director of IBD Centre
  • Hungarian Academy of Sciences: Doctor of Sciences (DsC) title
  • Semmelweis University: PhD title
  • Diploma of the European Board of Gastroenterology, EUMS (FEBG), AGA Fellow (AGAF)
  • Board certification: gastroenterology/hepatology
  • Board certification: internal medicine


Fellowship Training: 

Semmelweis University, Budapest, Hungary

Academic titles/speciality exams

Areas of expertise: 

Clinical Interests: inflammatory bowel diseases, general gastroenterology and therapeutic endoscopic including enteroscopy

Research Interests: His primary research interest is the epidemiology, outcome research, development of care pathways and quality indicators and complex prediction modelling (including biomarkers) of disease course and response to medical therapies in prediction of disease progression and response to medical therapy in inflammatory bowel diseases.

Selected publications: 


Books/book chapters: 26

Articles original/reviews&commentaries: 207/124

Invited and accepted lectures: 311

Impact factor without abstracts: 917.62

Citation (according to SCI-Scopus): 9201, H-index: 50

Selected 10 publications in the last 3 years:

1. Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL. Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade. Clin Gastroenterol Hepatol. 2019 Jan 7. pii: S1542-3565(19)30009-6 doi: 10.1016/j.cgh.2018.12.036

2. Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis—a Systematic Review Clin Gastroenterol Hepatol. 2018;16 2018 Dec 21. pii: S1542-3565(18)31397-1. doi: 10.1016/j.cgh.2018.12.021. [Epub ahead of print]

3. Reinglas J, Restellini S, Gonczi L, Kurti Z, Verdon C, Nene S, Kohen R, Afif W, Bessissow T, Wild G, Seidman E, Bitton A, Lakatos PL. Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. Dig Liver Dis. 2018 Dec 3. pii: S1590-8658(18)31232-5. doi: 10.1016/j.dld.2018.11.013

4. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, Nielsen KR, Brassard P, Vutcovici M, Bitton A, Bernstein CN, Leddin D, Tamim H, Stefansson T, Loftus EV Jr, Moum B, Tang W, Ng SC, Gearry R, Sincic B, Bell S, Sands BE, Lakatos PL, Végh Z, Ott C, Kaplan GG, Burisch J, Colombel JF. Sex-based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-based Studies from Western Countries. Gastroenterology. 2018;155:1079-89. pii: S0016-5085(18)34685-7. doi: 10.1053/j.gastro.2018.06.043

5. Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL. Long term efficacy, safety and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflammatory Bowel Disease. 2017;23:1908-15

6. Gecse KB, Lakatos PL IBD in 2016: Biologicals and biosimilars in IBD - the road to personalized treatment.Nat Rev Gastroenterol Hepatol. 2017;14:74-6. doi: 10.1038/nrgastro.2016.206

7. Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai A, Salamon A, Tóth GT, Vincze A, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play a more important role? J Crohns Colitis. 2017;11:697-705 DOI:10.1093/ecco-jcc/jjw203

8. Siegel CA, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DP, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C,

Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L Looking beyond symptoms and disease activity to define overall disease severity in inflammatory bowel disease: results of an IOIBD specialist panel. GUT 2018;67:244-54. doi: 10.1136/gutjnl-2016-312648

9. Vegh Z; Burisch; N Pedersen; I Kaimakliotis; D Duricova; M Bortlik; K Kofod Vinding; Avnstrøm S; J Olsen; KR Nielsen; KH Katsanos; EV Tsianos; L Lakatos; D Schwartz; S Odes; R D'Incà; M Beltrami; G Kiudelis; L Kupcinskas; A Jucov; S Turcan; L F Barros; F Magro; D Lazar; A Goldis; L de Castro; V Hernandez; O Niewiadomski; S Bell; P Munkholm; PL Lakatos Treatment steps; surgery and hospitalization rates during the first year of follow-up in patients with inflammatory bowel diseases from the 2011 ECCO-EpiCom inception cohort. JCC 2015;9:747-753 doi: 10.1093/ecco-jcc/jjv099

10. Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation Clin Gastroenterol Hepatol 2016;14(12):1685-1696. doi: 10.1016/j.cgh.2016.05.023

MUHC, Montreal General Hospital
Back to top